Clinical trials: Major Adverse Cardiac Event (MACE)
Coronary Artery Disease, Stent Restenosis
MACE in Different Drug-Eluting Stents
In this retrospective cohort study, all patients from Iranian registry were recruited and follow up after 5 years were recorded for MACE, and its relation to type and demographic data were evaluated
- Trial name
- NCT06470529
- Testing
- drug eluting stents
- Where
- Iran
- Volunteers
- 4,159 people
- Sponsor
- Shiraz University of Medical Sciences
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
Prehospital Point-of-Care Hs-Troponin I for Rule-Out of Acute Myocardial Infarction in Patients Without ST-Segment Elevation
People who call emergency medical services (EMS) with chest pain or other possible heart-related symptoms are often taken to hospital for further testing.
- Trial name
- Pre-POCT TnI (NCT07563998)
- Testing
- Prehospital high-sensitivity cardiac troponin I measurement
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- Central Denmark Region
Chronic Total Occlusion (CTO), Chronic Coronary Syndrome
FAPI Imaging Predicts Adverse Cardiac Events in Chronic Total Occlusion
Prospective, observational, single-center cohort study Hypothesis Higher myocardial FAPI uptake in CTO patients predicts a greater incidence of major adverse cardiovascular events (MACE) within 12 months after PCI.
- Trial name
- FACT-2 (NCT07020858)
- Testing
- FAPl lmaging
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Lin Zhao
Rheumatoid Arthritis, Major Adverse Cardiac Events
Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL
The rationale of our study is to observe the incidence of MACE in RA patients treated with tofacitinib along with statins with one or more cardiovascular disease risks.
- Trial name
- TOFSTAT (NCT07554820)
- Testing
- Tofacitinib 5 MG
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Shaikh Zayed Hospital, Lahore
Hypercholesterolemia, Type 2 Diabetes
Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments
The study is being conducted to compare the effect of standard treatment (target LDL-C level: <120 mg/dL (JASGL 2007 target level)) and intensive treatment (target LDL-C level: <70 mg/dL) in the prevention of major adverse…
- Conditions
- Hypercholesterolemia, Type 2 Diabetes, Hypertension
- Trial name
- POSITIVE (NCT01173939)
- Testing
- Pravastatin, Rosuvastatin
- Where
- 317 sites in Japan
- Volunteers
- 10,000 people
- Sponsor
- Positive Trial Group
Hypertension, Stroke
A Cluster-Randomized Controlled Trial
The goal of this study is to learn if an AI-generated personalized health report combined with face-to-face guidance from cardiologists can help rural adults with high blood pressure control their blood pressure better and reduce…
- Conditions
- Hypertension, Stroke, Cardiovascular, Coronary Heart Disease
- Trial name
- NCT07845448
- Testing
- AI-powered personalized health report with cardiologist consultation and prescription optimization, Integrated management (follow-up, education, quality control) without AI report and cardiologist consultation
- Volunteers
- 14,400 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Pericarditis, Tako-TSUBO Cardiomyopathy
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
INFLAME-BANK is a French multicenter prospective observational ancillary study of the international EACVI-INFLAME project. It aims to establish a biobank and perform immunophenotyping and proteomic analyses in patients with…
- Conditions
- Pericarditis, Tako-TSUBO Cardiomyopathy, Myocarditis, Inflammatory Cardiomyopathies
- Trial name
- INFLAME-BANK (NCT07737470)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Artery Disease
Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
Coronary artery disease is the leading cause of death in USA. Contemporary cardiac care has substantially reduced mortality and morbidity in patients with severe coronary artery disease.
- Trial name
- NCT00868855
- Testing
- Bradykinin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Vanderbilt University
Chronic Coronary Syndrome
CTFFR and Prediction of Non-Significant CAD Lesions
In this prospective cohort study, 250 patients with suspected or known CAD and at least one intermediate coronary lesion (50-70% stenosis) who had a NiFFR value greater than 0.80 underwent coronary computed tomography angiography…
- Trial name
- NCT06979427
- Testing
- NIFFR
- Where
- Iran
- Volunteers
- 250 people
- Sponsor
- Shiraz University of Medical Sciences
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE ONYX China RCT Study
It is a randomized controlled trial to evaluate the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in comparison with the Medtronic Resolute Integrity™ Zotarolimus-Eluting coronary…
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- NCT03466151
- Testing
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
- Where
- 2 sites in China
- Volunteers
- 550 people
- Sponsor
- Medtronic Vascular
Bleeding, Thrombosis
Occurrence of Bleeding and Thrombosis During Antiplatelet Therapy in Non-cardiac Surgery
Research questions: 1. What is the absolute risk reduction for in-hospital major adverse cardiac events (MACE) associated with the use of dual anti-platelet therapy as compared with aspirin alone in this population? 2.
- Conditions
- Bleeding, Thrombosis, Cardiac Events
- Trial name
- OBTAIN (NCT01358422)
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 830 people
- Sponsor
- European Society of Anaesthesiology
Major Adverse Cardiac Events, Acute Myocardial Infarction (AMI)
Preoperative Cardiology Consultation and the Incidence of Major Adverse Cardiac Events（MACE）
This cohort study aims to determine when preoperative cardiology consultation is needed to reduce the incidence of major adverse cardiac events (MACE) in elderly patients undergoing non-cardiac surgery.
- Conditions
- Major Adverse Cardiac Events, Acute Myocardial Infarction (AMI), Cardiac Death, Sudden, Cardiac Arrest (CA)
- Trial name
- MACE (NCT06884436)
- Where
- China
- Volunteers
- 22,000 people
- Sponsor
- Chinese PLA General Hospital
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerosis
Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid
In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways.
- Trial name
- XATOA (NCT03746275)
- Testing
- Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid
- Where
- 18 sites in Argentina, Brazil and 16 more
- Volunteers
- 5,798 people
- Sponsor
- Bayer
Coronary Artery Disease, Coronary Restenosis
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant…
- Trial name
- NCT00426049
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 484 people
- Sponsor
- German Heart Institute
Cardiac Events
MACE CDS Software Master Enrollment Protocol
This protocol will collect real world EHR data to support the product development life cycle activities associated with developing the Major Adverse Cardiac Events (MACE) Clinical Decision Support (CDS) software.
- Trial name
- NCT06257628
- Testing
- Index Event
- Where
- 3 sites in United States
- Sponsor
- Beckman Coulter, Inc.
Myocarditis
Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine
This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.
- Trial name
- MACIS (NCT05438472)
- Testing
- data collection in healthcare professionals with COVID-19 mRNA vaccine booster
- Where
- Switzerland
- Volunteers
- 835 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
OSA, ACS - Acute Coronary Syndrome
Impact of OSA on Outcomes in Acute Coronary Syndrome
Elucidating the effects of obstructive sleep apnea (OSA) on cardiovascular outcomes in acute coronary syndrome (ACS) is crucial in risk assessments and therapeutic recommendations for affected individuals.
- Conditions
- OSA, ACS - Acute Coronary Syndrome, Major Adverse Cardiac Events
- Trial name
- ISAACS (NCT03793582)
- Testing
- ApneaLink Type III portable sleep study
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- MetroHealth Medical Center
Peripheral Arterial Disease, Myocardial Injury
Cardiovascular Risk in Peripheral Artery Disease Patients Undergoing Endovascular Revascularisation
This study will investigate heart-related complications in patients with peripheral arterial disease (PAD) undergoing endovascular revascularization procedures to improve blood flow in the legs.
- Conditions
- Peripheral Arterial Disease, Myocardial Injury, Troponin, NT-proBNP
- Trial name
- RISK (NCT07599540)
- Where
- Slovenia
- Volunteers
- 500 people
- Sponsor
- University Medical Centre Ljubljana
Major Adverse Cardiac Event (MACE)
How Clinical and Personal Information Shape Physicians' Risk Judgments
Physicians often form quick judgments about the risk for serious disease when interacting with patients. Underestimating risk can lead to underuse of diagnostic testing and untreated illness, which can worsen patient outcomes.
- Trial name
- NCT07162376
- Testing
- Personal Information Disclosure
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park